CA2241924A1 - Procede de mesure et de traitement fondes sur la presence de produits terminaux de glycosylation poussee dans le tabac et dans ses sous-produits de combustion - Google Patents

Procede de mesure et de traitement fondes sur la presence de produits terminaux de glycosylation poussee dans le tabac et dans ses sous-produits de combustion Download PDF

Info

Publication number
CA2241924A1
CA2241924A1 CA002241924A CA2241924A CA2241924A1 CA 2241924 A1 CA2241924 A1 CA 2241924A1 CA 002241924 A CA002241924 A CA 002241924A CA 2241924 A CA2241924 A CA 2241924A CA 2241924 A1 CA2241924 A1 CA 2241924A1
Authority
CA
Canada
Prior art keywords
tobacco
ages
age
smoke
glycotoxins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002241924A
Other languages
English (en)
Inventor
Anthony Cerami
Richard J. Bucala
Helen Vlassara
Henry W. Founds
Clara J. Cerami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Picower Institute for Medical Research
Synvista Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2241924A1 publication Critical patent/CA2241924A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
    • A24B15/36—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances containing a heterocyclic ring
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
    • A24B15/36—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances containing a heterocyclic ring
    • A24B15/365—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances containing a heterocyclic ring having nitrogen and sulfur as hetero atoms in the same ring
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24D—CIGARS; CIGARETTES; TOBACCO SMOKE FILTERS; MOUTHPIECES FOR CIGARS OR CIGARETTES; MANUFACTURE OF TOBACCO SMOKE FILTERS OR MOUTHPIECES
    • A24D3/00—Tobacco smoke filters, e.g. filter-tips, filtering inserts; Filters specially adapted for simulated smoking devices; Mouthpieces for cigars or cigarettes
    • A24D3/06—Use of materials for tobacco smoke filters
    • A24D3/14—Use of materials for tobacco smoke filters of organic materials as additive
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Materials Engineering (AREA)

Abstract

Procédés qui permettent de mesurer l'accumulation de produits terminaux de glycosylation poussée (AGE) et de réduire cette accumulation desdits produits, fondés sur la découverte selon laquelle ces AGE et leurs glycotoxines précédentes sont présents dans le tabac et dans ses sous-produits. Plus particulièrement, lesdits procédés sont fondés sur l'observation selon laquelle les sujets qui fument ou utilisent du tabac d'une autre manière présentent des taux élevés d'AGE par rapport à des sujets non fumeurs. Les procédés de la présente invention concernent la mesure des taux d'AGE chez ces deux types de sujets et dans le tabac et son sous-produit qu'est la fumée, et le traitement de ces sujets avec des agents capables d'entrer en réaction avec les produits de glycosylation afin soit d'éviter soit de réduire l'accumulation d'AGE dans le corps. Des procédés concernent également l'évaluation des tabacs pour déterminer leur état de stockage et leur capacité et potentiel organoleptiques, le traitement de l'atmosphère ambiante pour réduire le taux d'AGE, et le traitement des tabacs et des sous-produits de combustion afin d'en réduire les taux d'AGE. Par exemple, de l'air et d'autres échantillons peuvent être prélevés et évalués à l'aide d'un dosimètre ou dispositif analogue, pour déterminer si les taux d'AGE sont supérieurs à la normale, après quoi des mesures pourraient être prises pour améliorer l'air ambiant. Des filtres et dispositifs similaires destinés à éliminer les AGE de la fumée du tabac sont également décrits. Tous ces procédés et les matériaux correspondants sont décrits et inclus dans la présente invention.
CA002241924A 1995-12-26 1996-12-23 Procede de mesure et de traitement fondes sur la presence de produits terminaux de glycosylation poussee dans le tabac et dans ses sous-produits de combustion Abandoned CA2241924A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US921895P 1995-12-26 1995-12-26
US921995P 1995-12-26 1995-12-26
US60/009,219 1995-12-26
US60/009,218 1995-12-26

Publications (1)

Publication Number Publication Date
CA2241924A1 true CA2241924A1 (fr) 1997-07-03

Family

ID=26679210

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002241924A Abandoned CA2241924A1 (fr) 1995-12-26 1996-12-23 Procede de mesure et de traitement fondes sur la presence de produits terminaux de glycosylation poussee dans le tabac et dans ses sous-produits de combustion

Country Status (7)

Country Link
EP (1) EP0877943A1 (fr)
JP (1) JP2000507346A (fr)
CN (1) CN1211321A (fr)
AU (1) AU723649B2 (fr)
CA (1) CA2241924A1 (fr)
IN (1) IN191280B (fr)
WO (1) WO1997023783A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5921248A (en) * 1997-03-28 1999-07-13 The Picower Institute For Medical Research Tobacco combination product filter
EP1175155A4 (fr) * 1999-04-15 2005-10-19 Fox Chase Cancer Ct Procede destine a reduire la predisposition a la formation de tumeurs provoquees par la 3-desoxyglucosone et les precurseurs de cette substance
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
SE0400683D0 (sv) 2004-03-19 2004-03-19 Forskarpatent I Syd Ab Use of modified extracellular matrix proteins in diagnosis and treatment of a atherosclerosis
CN106353434B (zh) * 2016-10-21 2018-10-09 中国烟草总公司郑州烟草研究院 一种定量测定烟草中Amadori化合物的分析方法
CN106769349B (zh) * 2017-01-06 2020-01-21 上海君联医疗设备有限公司 血液中异常糖基化蛋白细胞的检测方法
CN107202843B (zh) * 2017-06-07 2019-08-30 贵州省烟草科学研究院 LC-MS/MS法同时测定烟草中游离氨基酸和Amadori化合物的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4665192A (en) * 1984-03-19 1987-05-12 The Rockefeller University 2-(2-furoyl)-4(5)-2(furanyl)-1H-imidazole
US5869534A (en) * 1992-05-21 1999-02-09 The Picower Institute For Medical Research Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom
US4827949A (en) * 1987-09-16 1989-05-09 Sunas Ernest C Method of treating tobacco and tobacco produced thereby
CA1332572C (fr) * 1988-01-29 1994-10-18 Anthony Cerami Methode et agents de prevention de la formation de taches sur les dents
US5624804A (en) * 1991-12-20 1997-04-29 The Rockefeller University Immunochemical detection of In vivo advanced glycosylation end products
CA2210684C (fr) * 1995-01-18 2008-01-15 Alteon Inc. Utilisation de composes de thiazolium pour empecher et inverser la formation de produits finis de glycosylation avancee

Also Published As

Publication number Publication date
CN1211321A (zh) 1999-03-17
EP0877943A1 (fr) 1998-11-18
AU723649B2 (en) 2000-08-31
WO1997023783A1 (fr) 1997-07-03
AU1345997A (en) 1997-07-17
JP2000507346A (ja) 2000-06-13
IN191280B (fr) 2003-10-25

Similar Documents

Publication Publication Date Title
Djordjevic et al. Self-regulation of smoking intensity. Smoke yields of the low-nicotine, low-‘tar’cigarettes
Foiles et al. Mass spectrometric analysis of tobacco-specific nitrosamine-DNA adducts in smokers and nonsmokers
Nicholl et al. Increased levels of advanced glycation endproducts in the lenses and blood vessels of cigarette smokers
Morrow et al. The isoprostanes: current knowledge and directions for future research
US6110968A (en) Methods for treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts
US5850840A (en) Methods for measurement and treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts
Malaveille et al. Levels of mutagens in the urine of smokers of black and blond tobacco correlate with their risk of bladder cancer
St. Charles et al. A comparison of nicotine dose estimates in smokers between filter analysis, salivary cotinine, and urinary excretion of nicotine metabolites
AU723649B2 (en) Methods for measurement and treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts
Rosenthal et al. Time-course of cigarette smoke contamination of clinical hydrogen breath-analysis tests.
WO1997023783A9 (fr) Procede de mesure et de traitement fondes sur la presence de produits terminaux de glycosylation poussee dans le tabac et dans ses sous-produits de combustion
WAAGE et al. Discrimination of smoking status by thiocyanate and cotinine in serum, and carbon monoxide in expired air
Tsou et al. Acrolein is involved in the synergistic potential of cigarette smoking–and betel quid chewing–related human oral cancer
Kraal et al. The response of polymorphonuclear leukocytes to chemotictic stimulation for smokers and non‐smokers
Schneider et al. Saliva cotinine levels as a function of collection method
US5854000A (en) Methods for measurement predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts
Charles et al. A robust method for estimating human smoked cigarette yields from filter analysis data
AU4252700A (en) Methods for measurement and treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts
Behera et al. Serum surfactant protein-A levels in chronic bronchitis and its relation to smoking
MXPA98005261A (en) Methods to measure and treat the pre-calculated calculation on the presence of final products of advanced glicosilation in tobacco and in its combust subproducts
Halmai et al. Cigarette smoke elicits relaxation of renal arteries
Tso et al. Simple correlation and multiple regression among leaf characteristics, smoke components, and biological responses of bright tobaccos
Elmahdi et al. Cytological changes and immunocytochemistry expression of p53 in oral mucosa among waterpipe users in the Kingdom of Saudi Arabia
Doolittle et al. The effect of exposure to nicotine, carbon monoxide, cigarette smoke or cigarette smoke condensate on the mutagenicity of rat urine
Schuh et al. Subjective and discriminative stimulus effects of two de-nicotinized cigarettes with different tar yields

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead